Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) updates on a clinical trial and mechanistic study of a solid oral dose formulation for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE